1.4.4-UACR

In an exploratory analysis of adult patients with CKD associated with T2D

KERENDIA reduced UACR relative to placebo across a broad range of CKD severity on top of standard of care

In the FOUNTAIN observational, retrospective analysis of KERENDIA

UACR reduction was observed in real-world clinical practice

Clinical trials

Real-world results

UACR reduction remained stable for the duration of the trial.

UACR

UACR reduction remained stable for the duration of the trial.

UACR

CI=confidence interval; CKD=chronic kidney disease; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio

FOUNTAIN Analysis

Study design

FOUNTAIN was a descriptive retrospective, single-cohort analysis of US patients with CKD associated with T2D who initiated KERENDIA between July 2021 and August 2023 and whose EHR records, open claims, and laboratory data were aggregated in the OM1 Real World Data Cloud (N=15,948). Median follow-up was 7.23 months.

Limitations

A retrospective assessment based on health records may have missing or erroneous data entry
Dosing information and background therapy were not collected as part of the study

Results

A total of 2137 patients had available UACR values at baseline and were included in the analysis. The closest UACR measurements to baseline, 4 months, and 12 months, respectively, were used.*

At month 4 (n=913):

At month 12 (n=443):

*Based on the following time windows: Baseline (-90 to 0 days), 4 months (32 to 152 days), and 12 months (275 to 455 days).

CI=confidence interval; CKD=chronic kidney disease; EHR=electronic health record; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio.

Trial Design CV Data Renal Data UACR Safety

IMPORTANT SAFETY INFORMATION AND INDICATIONS

CONTRAINDICATIONS:

Hypersensitivity to any component of this product
Concomitant use with strong CYP3A4 inhibitors
Patients with adrenal insufficiency

WARNINGS AND PRECAUTIONS:

Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia

Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5 mEq/L. Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium.
Worsening of Renal Function in Patients with Heart Failure: KERENDIA can cause worsening of renal function in patients with heart failure. Rarely, severe events associated with worsening renal function, including events requiring hospitalization, have been observed

Measure eGFR in all patients before initiation of treatment or with dose titration of KERENDIA and dose accordingly. Initiation of KERENDIA in patients with heart failure and an eGFR <25 mL/min/1.73 m² is not recommended. Measure eGFR periodically during maintenance treatment with KERENDIA in patients with heart failure. Consider delaying up-titration or interrupting treatment with KERENDIA in patients who develop clinically significant worsening of renal function

MOST COMMON ADVERSE REACTIONS:

CKD associated with T2D: From the pooled data of FIDELIO-DKD and FIGARO-DKD, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3%), and hyponatremia (1.3% vs 0.7%).
HF LVEF ≥40%: From FINEARTS-HF, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (9.7% vs 4.2%), hypotension (7.6% vs 4.7%), and hyponatremia (1.9% vs 0.9%). Events related to worsening renal function were reported more frequently in the KERENDIA group (18%) compared with placebo (12%).

DRUG INTERACTIONS:

Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice.
Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor, and adjust KERENDIA dosage as appropriate.
Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers.
Sensitive CYP2C8 Substrates at KERENDIA 40mg: Monitor patients more frequently for adverse reactions caused by sensitive CYP2C8 substrates if KERENDIA 40mg is co-administered with such substrates, since minimal concentration changes may lead to serious adverse reactions.

USE IN SPECIFIC POPULATIONS:

Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment.
Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B).

INDICATIONS:

KERENDIA (finerenone) is indicated to reduce the risk of:

sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) (10mg, 20mg tablets)
cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (HF LVEF) ≥40% (10mg, 20mg, 40mg tablets)

Please see the full Prescribing Information for KERENDIA.

CKD=chronic kidney disease; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio.

REFERENCES

KERENDIA reduced UACR relative to placebo across a broad range of CKD severity on top of standard of care

UACR reduction was observed in real-world clinical practice

FOUNTAIN Analysis

Study design

Limitations

Results

At month 4 (n=913):

At month 12 (n=443):

Placebo corrected UACR reduction was observed at month 4 and remained stable for the duration of the FIGARO-DKD trial37

Placebo corrected UACR reduction was observed at month 4 and remained stable for the duration of the FIDELIO-DKD trial38

Placebo corrected UACR reduction was observed at month 4 and remained stable for the duration of the FIGARO-DKD trial³⁷

Placebo corrected UACR reduction was observed at month 4 and remained stable for the duration of the FIDELIO-DKD trial³⁸